Biocon

Biocon Pharma gets GMP compliance certificate from UK's health regulator MHRA for Bengaluru facility

The certificate, which includes manufacturing and packaging of tablets and capsules in the non-potent and potent blocks of the facility, was issued based on a remote inspection

Biocon executive chairperson Kiran Mazumdar Shaw tests COVID-19 positive, says her symptoms are mild

'I have added to the COVID-18 count by testing positive. Mild symptoms and I hope it stays that way,' the 67-year-old biotechnology industry veteran said in a tweet

DCGI approves psoriasis injection for 'restricted emergency use' to treat COVID-19 patients

Drugs Controller General of India approved monoclonal antibody injection Itolizumab for limited use to treat moderate to severe cases of COVID-19.

Biocon Q4 net profit falls 42% to Rs 123 cr due to one-time COVID-19 impact; total income up 6%

Biotechnology major Biocon has reported a 42 percent decline in its consolidated net profit to Rs 123 crore for the quarter ended March 2020, mainly on account of the one-time coronavirus-related impact on its biologics business

Biocon chief Kiran Mazumdar-Shaw recognised among world s top 20 inspirational leaders in Biopharma

Biocon Ltd announced on Monday that The Medicine Maker Power List 2020 has ranked its Executive Chairperson Kiran Mazumdar-Shaw as one of the world's top 20 inspirational leaders in the field of biopharmaceuticals

Biocon Biologics receives EIR from USFDA for two manufacturing facilities in Bengaluru

Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., said on Thursday it has received the Establishment Inspection Report (EIR) from the USFDA (the United States Food and Drug Administration) for the pre-approval inspection at two of its biologics manufacturing facilities in Bengaluru

Biocon, Biocon Biologics activate business continuity plans across functions in wake of COVID-19

Biocon will continue to operate essential pharmaceutical manufacturing in full compliance with government requirements, it added.

Citizenship Amendment Act: Microsoft chief Satya Nadella's views are modern and progressive, and subtly question new law

A day after Microsoft CEO Satya Nadella termed situation surrounding the Citizenship Amendment Act as "sad", his company on Tuesday issued a far subtler statement on the contentious Act, that conveyed his optimism for an immigrant in India who could benefit the society and economy

Biocon appoints MB Chinappa as CFO of Biocon Biologics; to be part of company's executive leadership team

Chinappa joins Biocon Biologics from Biocon's subsidiary company Syngene International Ltd, where he was President (Finance) and CFO since 2008, the company said in a filing to the BSE.

Karvy case gets murkier, who benefited the most from India's economic growth; all this and more on Moneycontrol Pro

The Karvy case is becoming messier by the day and threatens to take down an important segment of the market—loans against shares (LAS)— albeit for the short term.